论文部分内容阅读
目的通过检测糖尿病肾病合并冠心病患者血浆高敏C反应蛋白(hsCRP)及巨噬细胞移动抑制因子(MIF),了解hsCRP及MIF在糖尿病肾病合并冠心病患者中的变化,协助临床决策。方法收入64例糖尿病肾病合并冠心病患者及57例糖尿病肾病但无明确冠心病依据的患者,同时收入54例健康志愿者,以ELISA法检测分析其血浆中高敏C反应蛋白及巨噬细胞移动抑制因子的变化。结果糖尿病肾病合并冠心病组患者血浆hsCRP水平(9.93±2.58)mg/L及MIF水平(23.61±6.64)μg/L高于无明确冠心病依据的患者[hsCRP(7.37±1.32)mg/L,MIF(15.56±3.70)μg/L],差异有统计学意义(P均<0.05),两组患者血浆hsCRP及MIF水平又均显著高于对照组[hsCRP(3.51±2.00)mg/L,MIF(9.57±1.25)μg/L]。结论检测糖尿病肾病患者血浆hsCRP及MIF,可能有助于鉴别糖尿病肾病患者有无合并冠心病的危险。
Objective To detect the changes of plasma hsCRP and MIF in patients with diabetic nephropathy and coronary heart disease and to understand the changes of hsCRP and MIF in patients with diabetic nephropathy complicated with coronary heart disease and to assist in clinical decision-making. Methods Sixty-four patients with diabetic nephropathy with coronary heart disease and 57 patients with diabetic nephropathy who did not have definite coronary heart disease were enrolled. At the same time, 54 healthy volunteers were enrolled. The plasma high-sensitivity C-reactive protein and macrophage migration inhibition Factor changes. Results The plasma levels of hsCRP (9.93 ± 2.58) mg / L and MIF (23.61 ± 6.64) μg / L in patients with diabetic nephropathy complicated with coronary heart disease were significantly higher than those with no definite coronary heart disease [hsCRP (7.37 ± 1.32) mg / MIF (15.56 ± 3.70) μg / L], the difference was statistically significant (all P <0.05). The plasma hsCRP and MIF levels in both groups were also significantly higher than those in the control group [hsCRP (3.51 ± 2.00) mg / (9.57 ± 1.25) μg / L]. Conclusion Detection of plasma hsCRP and MIF in patients with diabetic nephropathy may be helpful in differentiating patients with and without diabetic nephropathy from being at risk of coronary heart disease.